GLENMARK PHARMACEUTICALS
|
|
| BOM : 532296 NSE : GLENMARK | |
| LT :
Long Term Analysis
Fundamentals : Average
Valuation : Good [Stock is Cheap] Debt : High |
Updated: |
| ST :
Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : None or < 25% |
May 20,2022 |
|
Price(EOD): ₹ 407.40
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 11,496.83 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| GLENMARK PHARMACEUTICALS | 3.8% | -10.9% | -35.5% |
| SUN PHARMACEUTICAL INDUSTRIES | 3.4% | -0.8% | 28% |
| DIVIS LABORATORIES | 2.1% | -3.3% | 4.4% |
| DR REDDYS LABORATORIES | 9.2% | -1.1% | -24.4% |
| CIPLA | 4.9% | -3.3% | 6.1% |
| GLAND PHARMA | -1.3% | -6.3% | 1% |
| PIRAMAL ENTERPRISES | 2.3% | -13.7% | 12% |
| CADILA HEALTHCARE | 3.5% | -0.9% | -44% |
| TORRENT PHARMACEUTICALS | 3.1% | -6.9% | -4.9% |
FUNDAMENTAL ANALYSIS OF GLENMARK PHARMACEUTICALS
[ Q(TTM): Dec2021, Y: Mar2021
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF GLENMARK PHARMACEUTICALS
[As on : May 20,2022
]
| Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
11.85
P/E Calculated based on EPS of 34.38
[ Mar2021 - Consolidated Results ] 1.63
P/B Calculated based on Book Value of 249.6
[ Mar2021 - Consolidated Results ] 0.95
P/S Calculated based on Revenues of 12145.7 Cr
[ TTM - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
-60% -68% -66% |
SHARE PRICE MOMENTUM OF GLENMARK PHARMACEUTICALS
GLENMARK PHARMACEUTICALS vs SENSEX
DEBT OF GLENMARK PHARMACEUTICALS
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2021 2020 2019 Avg_3yrs |
0.25 0.27 0.26 0.26 |
0.67 0.8 0.8 0.76 |
|
[Last Annual Data : Mar2021]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF GLENMARK PHARMACEUTICALS
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Mar2022 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF GLENMARK PHARMACEUTICALS
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
0.83% 17.45% -10.89% -12.76% |
13.87% 30.77% -1.42% -3.4% |
| QtrlyTrend |
0 | |
| Latest Qtr: Dec2021 | ||
| Quarterly Result Analysis → | ||
GLENMARK PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE MIDSMALLCAP | 3.7% | -8.4% | 12.6% |
| S&P BSE 400 MIDSMALLCAP | 3.6% | -7.9% | 11.9% |
| S&P BSE 150 MIDCAP | 3.3% | -7% | 11.5% |
| S&P BSE ALLCAP | 3.2% | -5.8% | 10.3% |
| S&P BSE MID CAP | 3.2% | -8% | 8% |
| S&P BSE 500 | 3.2% | -5.6% | 9.7% |
| S&P BSE LARGE MIDCAP | 3.1% | -5.2% | 9.2% |
| S&P BSE 250 LARGEMIDCAP | 3.1% | -5.3% | 9.5% |
| S&P BSE HEALTHCARE | 2.8% | -6.4% | -4.8% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY PHARMA | 3.5% | -3.4% | -5.7% |
| NIFTY MID SMALL400 | 3.4% | -8% | 12.5% |
| NIFTY500 MULTICAP 50:25:25 | 3.4% | -6.8% | 11% |
| NIFTY 500 | 3.1% | -5.7% | 9.7% |
| NIFTY HEALTHCARE | 3% | -6.2% | -3.4% |
| NIFTY 200 | 3% | -5.3% | 9.3% |
| NIFTY LARGE MIDCAP 250 | 3% | -6% | 10.5% |
| NIFTY MIDCAP150 | 2.9% | -7.1% | 12% |
| NIFTY FREE MIDCAP 100 | 2.9% | -7.3% | 12.3% |
You may also like the below Video Courses
FAQ about GLENMARK PHARMACEUTICALS
Is GLENMARK PHARMACEUTICALS good for long term investment?
As on May 20,2022, the Fundamentals of GLENMARK PHARMACEUTICALS look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of GLENMARK PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is GLENMARK PHARMACEUTICALS UnderValued or OverValued?
As on May 20,2022, GLENMARK PHARMACEUTICALS is Under Valued based on the estimates of intrinsic value and hence may be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of GLENMARK PHARMACEUTICALS ?
As on May 20,2022, the Intrinsic Value of GLENMARK PHARMACEUTICALS is Rs. 1,201.67 determined based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 1,021.86
Fair Value [Median EV / Sales Model] : Rs. 1,276.50
Fair Value [Median Price / Sales Model] : Rs. 1,201.67
Median Fair Value of GLENMARK PHARMACEUTICALS : Rs. 1,201.67
Is GLENMARK PHARMACEUTICALS trading at a Premium or Discount?
As on May 20,2022, GLENMARK PHARMACEUTICALS is trading at a Discount of -66% based on the estimates of Median Intrinsic Value!
Check out Annual Financials of Industry Peers
Check out Quarterly Results of Industry Peers
Compare Analytics
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].
